Myasthenia Gravis Clinical Trials

• Presence of autoantibodies to AChR or MuSK

• Myasthenia Gravis Foundation of America (MGFA) Class II-IV

• MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit

• QMG total score of ≥11 at screening an confirmed at baseline visit

• Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms

• On a stable dose of glucocorticoids and/or other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required

• No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening

• No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen)

• No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening

⁃ Able and willing to attend the necessary visits to the study site